Page 55 - 2025中醫藥與天然藥物聯合學術研討會-中醫藥與天然藥物的挑戰Ｘ機遇與未來大會手冊

王陸海 教授 Lu-Hai Wang, PhD

◼ Position/Affiliation/E-mail

Position/Affiliation:
Director, Chinese Medicine Research Center; Chair Professor, Graduate
Institute of Integrated Medicine, China Medical University (CMU), Taiwan.
E-mail: luhaiwang@mail.cmu.edu.tw

◼ Biography

Professor Lu-Hai Wang’s expertise lies in cancer biology, oncology, signal transduction,
microbiology, virology, etc., dedicating to promoting Chinese herbal medicine, new drug
development, and acupuncture. He has completed a technology transfer project, established a

spin-off company, and had approx. 150 SCI publications. His research encompassed the
discovery of new oncogenes and their characterization, the exploration of molecular signaling,
molecular mechanisms of carcinogenesis and metastasis, including. In recent years, his team
has been devoting efforts on the development of new cancer therapeutics including 2 antibody
drugs, as well as botanical extracts and formulations in inhibiting tumor growth, metastasis and

recurrence.
 Determined the location of the first oncogene known to mankind, src, within the genome
of the sarcoma virus RSV (Rous sarcoma virus) and completed the mapping of four RSV
genes within its genome.
 Discovered the new sarcoma genes fps (Fujinami sarcoma virus oncogene) and ros
(Rochester sarcoma virus oncogene), clarified their functions, and completed sequence
analysis of the ros oncogene.
 Confirmed that the oncogene src originates from normal cells and clarified the molecular
mechanism by which the src gene is transduced from normal cells to the genome of the
sarcoma virus RSV.
 Demonstrated that signaling molecules including Vav3, Twis, RACK1, AKT2, and Stat3
play a key role in promoting the invasiveness of the ROS oncogene.
 Demonstrated that specific miRNAs and their signaling pathways control the metastatic
potential of breast, ovarian, and oral cancers, and explain their potential clinical
translational applications.
 Demonstrated that specific molecules including transketolase and CD24 can regulate the
metastatic potential of breast cancer.
 Demonstrated that the specific molecule cystathionine-r-lyase can regulate the metastatic
potential of prostate cancer.
 Developed two humanized monoclonal antibodies as potential new anticancer drugs, each
has filed USA and Taiwan patents.
 Developed a compound herbal formulation for inhibiting cancer metastasis and recurrence
 Developed a botanical extract that specifically inhibit cancer stem cells and filed USA and
Taiwan patents

33